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Chronic obstructive pulmonary disease is a major cause of increased morbidity and
mortality. The aim of this study was to investigate hospital admission rates among
individuals with symptoms of chronic bronchitis and among those with airflow limitation
corresponding to GOLD stages 1–4.
Method: Between 1974 and 1992, 22 044 middle-aged individuals participated in a health
screening, which included spirometry (without broncho-dilation), as well as recording of
respiratory symptoms and smoking habits. Information on hospital admissions until 31
December 2002 was obtained from local and national registers. The hospital admission
rates due to all causes, obstructive lung disease and cardiovascular disease were analysed
among individuals with symptoms of chronic bronchitis and among those with airflow
limitation corresponding to GOLD stages 1–4 using ordinal regression with adjustment for
age and with individuals with normal lung function and without symptoms of chronic
bronchitis as reference group.
Results: Symptoms of chronic bronchitis and GOLD stages 1–4 showed increased hospital
admission rates (hospital admission rates due to obstructive lung disease excluded) among
smokers of both genders. Furthermore, symptoms of chronic bronchitis showed increased
hospital admission rates due to obstructive lung disease among smoking women. There
were also increased hospital admission rates due to obstructive lung disease amongElsevier Ltd. All rights reserved.
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M. Ekberg-Aronsson et al.110smokers of GOLD stages 1–4 and increased hospital admission rates due to cardiovascular
disease among female smokers of GOLD stage 2.
Conclusion: Among smokers, symptoms of chronic bronchitis as well airflow limitation
corresponding to GOLD stages 1–4 conveyed a substantial morbidity with increased hospital
admission rates due to all causes. The burden of disease is most likely underestimated
among individuals with symptoms of chronic bronchitis and chronic obstructive pulmonary
disease.
& 2007 Elsevier Ltd. All rights reserved.Background
Chronic obstructive pulmonary disease (COPD) is a leading
cause of increased morbidity and mortality.1 It is estimated
that COPD ranks fifth as a worldwide burden of disease by
2020.2 With the aim of increasing awareness of COPD and
decreasing morbidity and mortality from the disease, the
Global initiative for Chronic Obstructive Lung Diseases
(GOLD) guidelines were published in 20011 thereafter
revised 2003, 2004, 2005 and 2006.3 According to GOLD,
COPD is a disease state characterized by airflow limitation
that is not fully reversible. The airflow limitation is usually
both progressive and associated with an abnormal inflam-
matory response to noxious particles and gases.1 The early
development and progression of COPD is yet not clarified
and many questions remain.4 An at-risk stage GOLD stage 0
(chronic cough and sputum production, normal spirometry)
was introduced in 2001 in the GOLD classification of COPD.
The relevance of symptoms of chronic bronchitis and thus of
GOLD stage 0 as a risk factor for COPD development has
been debated.5 It has been recognised that some smokers
may develop COPD without having symptoms of chronic
bronchitis in the early stages of the disease whereas other
smokers with symptoms of chronic bronchitis may not
develop COPD at all.3,6 Due to incomplete evidence that
individuals who meet the definition of stage 0 necessarily
progress to stage 1, mild COPD, the stage 0 that appeared in
previous classifications is no longer included as a stage of
COPD.3 However, the current GOLD guidelines underlines
that chronic cough and sputum production are not normal
and the underlying cause should be searched for.3 Although
thus perhaps not associated with COPD development,
symptoms of chronic bronchitis could nevertheless be of
importance with respect to long-term morbidity in affected
individuals. These aspects are not very well studied
despite the fact that the disorder is very common, especially
among smokers.
In established COPD an important aspect of morbidity are
the periods of worsening of the disease, exacerbations,
which are common and place a burden on the patient7 and
health services.8 An exacerbation may require physician
consultation in primary or secondary care, and may result in
a hospital admission and even lead to death.8 Furthermore it
is recognised from epidemiological studies that individuals
with reduced lung function have an increased risk of
cardiovascular disease independent of smoking.9 In some
previous studies, co-morbid conditions such as cardiore-
spiratory disorders and respiratory cancer were more
common among patients with COPD. Furthermore, patients
with COPD also showed higher risks of hospital admissionsand death due to cardiovascular disease.10–12 There are,
however, few population-based studies on the influence of
COPD on subsequent long-term morbidity. COPD is often
under-diagnosed13 and such studies could also encompass
the morbidity among individuals with airflow limitation but
without a known COPD diagnosis.
The aims of this study were to investigate the total,
obstructive lung disease and cardiovascular morbidity as
reflected in hospital admission rates among individuals with
symptoms of chronic bronchitis and among those with
airflow limitation corresponding to GOLD stages 1–4.
Study population and methods
The Malmo¨ Preventive project
With a population of 250 000 inhabitants, Malmo¨ is Sweden’s
third largest city. The Malmo¨ Preventive programme (MPP),
a preventive, case-finding programme for cardiovascular risk
factors and alcohol abuse was created in 1974 at the
Department of Preventive Medicine of Malmo¨ University
Hospital. The aim of this programme was to screen large
strata of the adult population, mostly middle-aged men and
women born in pre-specified years, in order to find high-risk
individuals for preventive intervention.14,15 All individuals
who participated in the MPP took part in a comprehensive
health screening, which included a physical examination,
spirometry and blood tests. Additionally, lifestyle-related
risk factors were assessed by means of a self-administered
questionnaire including questions on smoking habits. The
questions regarding smoking habits and tobacco consump-
tion varied during the screening period and thus between
cohorts. Some cohorts did not receive a detailed ques-
tionnaire regarding tobacco consumption and some cohorts
did not perform a spirometry. Various interventions (lifestyle
modification, drug therapy) were offered to nearly 25% of
the screened individuals for shorter or longer periods.14,16
Intervention against smoking was, however, only instituted if
another cardiovascular risk factor was present and consisted
of advice given by a nurse to stop smoking, sometimes
supported by the measurements of carboxy-haemoglobin
(COHb) and feedback information to the individual with a
history of smoking.17
Study population
Between 1974–1992 whole age-cohorts were invited to the
programme with an overall attendance rate of 70 percent
(range 64–78) resulting in a total of 33 346 screened
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Figure 1 Flow-chart of the study population.
Hospital admission rates with symptoms of CB and airflow limitation corresponding to the GOLD stages of COPD 111individuals, 22 444 men (mean age 44 years range 27–61) and
10 902 women (mean age 50 years, range 28–58).16 The
present study was based 22 044 individuals 14 630 men and
7414 women from with detailed information regarding their
tobacco consumption and who had also performed lung
function tests. The study population and exclusions have
been described in a previous study18 and in a flow-chart of
the study population (Figure 1).
Assessment of smoking habits
Tobacco smoking is a well-known risk factor for COPD
development. People who have never smoked with respira-
tory symptoms or with signs of airflow limitation are more
likely to have a diagnosis of asthma.6 Ex-smokers with
respiratory symptoms or signs of airflow limitation consti-
tute a heterogeneous group who might have both a diagnosis
of COPD and asthma. In this study we therefore categorised
the individuals according to their self-reported smoking
habits into never-smokers, ex-smokers and current smokers,
and all analyses were stratified accordingly. Those who gave
negative answers on all smoking-related questions regarding
current and previous smoking habits were classified as
never-smokers. Individuals who stated that they had
stopped smoking and who gave negative answers on all
other smoking-related questions were classified as former
smokers. Individuals who stated that they were currently
smoking were classified as smokers. Those who gave
contradictory answers were excluded. The self-reported
smoking habits have previously been validated with mea-
surements of COHb.19
Assessment of pulmonary function
Pulmonary function was assessed by a screening spirometry.
A Spirotrons apparatus (Dra¨gerwerk AG, L +ubeck, Germany)
was used, with the individual in an upright standing position
without a nose clip. Specially trained nurses performed the
tests. Forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) were recorded. One acceptable manoeuvre
with respect to the individual’s cooperation and perfor-
mance was required.20 No reversibility test was performed.FEV1 was analysed as percentage of predicted (pred) values.
Predicted values of FEV1 were obtained from internally
derived linear regressions based on height and age in a
subgroup of 3467 male and 2961 female never-smokers.18
Men : Pred: FEV1 ðLÞ : 4:422 height ðmÞ  0:0381
 age ðyearÞ  2:483; SD 0:63,
Women : Pred:FEV1 ðLÞ : 3:615 height ðmÞ  0:0217
 age 2:134; SD 0:45.
Assessment of respiratory symptoms
Respiratory symptoms were assessed by a self-administered
questionnaire. Individuals who stated that they recently or
previously had had episodes with chronic productive cough
lasting more than 3 months, more than 2 consecutive years
were regarded as having symptoms of chronic bronchitis.18Classification of pulmonary function
Symptoms of chronic bronchitis and GOLD Stages 1–4 were
defined as follows:
Symptoms of chronic bronchitis: FEV1/FVCX0.70 and
FEV1X80% pred and symptoms of chronic bronchitis as
defined above.
Stage 1 (mild): FEV1/FVCo0.70 and FEV1X80% pred;
Stage 2 (moderate): FEV1/FVCo0.70 and FEV1o80% pred
and FEV1X50% pred;
Stage 3 (severe): FEV1/FVCo0.70 and FEV1o 50% pred
and FEV1X30% pred;
Stage 4 (very severe) : FEV1/FVCo0.70 and FEV1o30%
pred.
Individuals without symptoms of chronic bronchitis
and with FEV/FVCX0.70 and FEV1X80% predicted were
classified as normal and used as a reference group
throughout the study. Individuals who could not be classified
into any of these categories were labelled as ‘‘non-
classifiable’’.18
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All individuals were followed in local and national registers
for hospital admissions until 31st December 2002. The local
patient register of Malmo¨ started in 1974 and was completed
in 1979. The Swedish Board of Health and Welfare provided
data from the National Patient Registry on hospital admis-
sions from 1987 and onwards. The register contains
information regarding hospital admissions, diagnoses, date
of admission, age and national identification number.
Missing information regarding hospital admissions is esti-
mated to be less than 1% per year. Information on primary
diagnoses is missing in approximately 1% of the hospital
admissions.21 In this study only hospital admissions after
screening due to somatic diseases were included. Person-
years when individuals were hospitalised were excluded.
The vital status was unknown in 412 individuals who had left
the country. The accumulated person-years until they left
the country were used in the analyses. Both the primary and
the secondary hospital discharge diagnoses of COPD, asthma
and cardiovascular disease were used. Hospital discharge
diagnoses of COPD and asthma may overlap.4 The term
‘‘obstructive lung disease’’ was therefore used, comprising
both COPD and asthma. The following International Classi-
fication of Diseases (ICD) codes were used to define cause
specific hospital admissions: COPD: ICD 8; 490–492 and 496,
ICD 10; J40–44, asthma: ICD 8; 493, ICD 10; J45, and
cardiovascular disease: ICD 8–9; 401–414, 424, 426–429,
431–444; ICD 10; I10–25, I34–37, I44–49, I50–52, I61–71.Statistical analysis
The computer-based analysis programme, Statistical Pro-
gramme for Social Sciences (SPSS) version 11.0, was used for
all calculations. The number of hospital admissions per 1000
person-years due to all causes, obstructive lung disease and
cardiovascular disease was calculated for each individual.
Differences in hospital admission rates in GOLD stages 1–4
and in the group with symptoms of chronic bronchitis were
analysed with individuals with normal lung function and
without symptoms of chronic bronchitis as reference. The
distribution of hospital admission rates was skewed. It was
therefore necessary to use a non-parametric statistical
method. Increasing age may also increase the number of
hospital admissions and we regarded the adjustment for age
as essential in the analyses. Ordinal regression is a relatively
new statistical method which was developed for analyses of
ranked outcomes.22 The model allows for adjustments for
covariates such as age which is not possible with most non-
parametrical statistical analyses. Therefore, in order to
compare the hospital admission rates between the GOLD
stages, the hospital admission rates were ranked and
categorized and used as outcome in an ordinal regression
model which also incorporated adjustment for age. All
analyses were stratified for gender and smoking habits. In
the analyses of hospital admission rates due to all causes,
hospital admissions due to obstructive lung disease were
excluded. In each of the GOLD stages, subgroups of
individuals accounted for many of the hospital admissions.
In some groups the majority of the individuals showed no
hospital admissions at all. In order to clarify the fact that asmall proportion of the individuals accounted for many
events and for comparison of admission rates between
groups, the 25th, 50th and 75th percentile (hospital
admission rates), the 50th, 75th and 95th percentiles
(hospital admission rates due to cardiovascular and obstruc-
tive lung disease) were calculated and the data presented in
box-plot figures accordingly. This way of presenting the data
is also in line with the non-parametric statistical method
used in our analyses as described above.22 Several analyses
were performed; some of them with statistical significance
(P-value less than 0.05) may be due to chance. P-values
above 0.01 should therefore be interpreted with caution.
Results
Descriptive information
The study comprised 14 630 men and 7414 women in total.
The mean age at baseline (years, standard deviation in
brackets) in men was 46.4 (5.7) and 47.5 (7.8) in women.
Among men the proportion of smokers was 49%, ex-smokers
27% and never-smokers 24%. The corresponding figures
among women were 44%, 16% and 40%. Among men, the
prevalence of symptoms of chronic bronchitis and GOLD
stages 1–4 was 2.2%, 9.9%, 6.9%, 1.0% and 0.3%. The
corresponding figures among women were 2.4%, 4.5%, 4.3%,
0.6% and 0.2%, respectively. Table 1 shows the distribution
of hospital admissions by gender. About one-third of the
individuals had no hospital admissions during the follow-up
time. The prevalence of COPD according to age and gender
is shown in Table 2. The proportions of non-classifiable
individuals were 1453 (9.9%) among men and 821 (11.0%)
among women.17 The numbers of individuals and hospital
admissions in the GOLD stages are shown in Tables 3 and 4.
The numbers of deaths during the follow-up time were 4365
(30%) in men and 1047 (14%) in women.
Hospital admissions due to all causes
A total of 71 813 hospital admissions was recorded in the
study population based on 461 943 person-years (155 per
1000 person-years). Of these, the information on principal
diagnosis was missing in 1388 (1.9%). A total of 22 341
hospital admissions also had a secondary diagnosis. The total
number of person-years excluded, because the individuals
were admitted to hospital, was 1336. Among men a total of
52 484 hospital admissions was recorded based on 317 508
person-years (165 per 1000 person-years). Among women
the number of hospital admissions was 19 329 based on
144 435 person-years (134 per 1000 person-years). Numbers
of individuals, patients and hospital admission in the GOLD
stages and among those with symptoms of chronic bronchitis
is shown in Tables 3 and 4.
Hospital admissions rates in symptoms of chronic
bronchitis and GOLD stages 1–4
The hospitalisation admission rates were increased among
male and female smokers with symptoms of chronic
bronchitis (Figure 2, Table A1 in Appendix A). The rates
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Table 1 Number of hospital admissions during follow-up by gender.
Number of
hospital
admissions
Men Women
N Percent Cumulative
percent
N Percent Cumulative
percent
0 3944 27.0 27.0 2445 33.0 33.0
1 2604 17.8 44.8 1657 22.3 55.3
2 1771 12.1 56.9 998 13.5 68.8
3–5 3207 21.9 78.8 1323 17.8 86.6
6–10 1974 13.5 92.3 641 8.6 95.3
11–15 676 4.6 96.9 202 2.7 98.0
16–20 246 1.7 98.6 81 1.1 99.1
21–30 142 1.0 99.5 50 0.7 99.8
31–40 43 0.3 99.8 10 0.1 99.9
X41 23 0.2 100 7 0.1 100
14 630 100 7414 100
Table 2 Distribution of age groups and prevalence of
COPD (GOLD stages 1–4) at baseline screening according
to gender and age groups.
Age group
(years)
N (%) COPD in age
group (%)
Men
o29 518 (3.5) 4.2
30–34 0 (0.0) 0
35–39 899 (6.1) 11.6
40–44 2943 (20.1) 13.4
45–49 9043 (61.8) 19.8
50–54 72 (0.5) 19.4
55–59 547 (3.7) 28.0
60–64 608 (4.2) 27.8
Total 14 630 (100)
Women
o29 591 (8) 4.0
30–34 6 (0.1) 0
35–39 921 (12.4) 7.9
40–44 905 (12.2) 5.4
45–49 1452 (19.6) 9.2
50–54 1846 (24.9) 10.2
55–59 1693 (22.8) 14.4
Total 7414 (100)
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men and in GOLD stages 2 and 4 among smoking women
(Figure 2). Among ex-smokers and never-smokers with
symptoms of chronic bronchitis and GOLD stages 1–4 there
were no increased hospital admission rates.Hospital admission due to obstructive lung disease
The total number of hospital admissions due to either COPD
or asthma, both primary and secondary diagnoses (hospitaladmissions due to obstructive lung disease), was 2326.
A total of 756 individuals in the study population
were hospitalised at least once due to obstructive lung
disease as defined above. There were 1067 (1.5%) of hospital
admissions with COPD as the primary diagnosis and 851
with COPD as secondary diagnosis. There were 392 (0.5%)
hospital admissions with asthma as the primary diagnosis
and 187 with asthma as the secondary diagnosis. The
hospital discharge diagnoses of COPD and asthma
overlapped. Among hospital admissions with COPD as the
primary diagnosis, 34 (3.2%) had asthma as a secondary
diagnosis. Furthermore, of all hospital admissions with the
primary diagnosis of asthma, 45 (11.5%) had COPD as a
secondary diagnosis. Moreover, among a total of 386
individuals who had been hospitalised at least once with
COPD as the primary diagnosis, 55 (14%) had also been
hospitalised at least once with asthma as the primary
diagnosis.Hospital admission rates due to obstructive lung
disease in symptoms of chronic bronchitis and GOLD
stages 1–4
Increased hospital admission rates due to obstructive
lung disease were found among those with symptoms
of chronic bronchitis among smoking women and ex-smoking
men as compared to the reference-group of individuals
without symptoms of chronic bronchitis and with normal
pulmonary function (Figure 3, Table A2 in Appendix A).
Notably, among for instance smoking women with symptoms
of chronic bronchitis, only a small subgroup (Xthe 95th
percentile) showed increased rates with 55 hospital
admissions per 1000 person-years or more as compared
to the 95th percentile of the reference-group which
showed zero hospital admissions. The hospital admission
rates also showed statistically significant increase among
male and female smokers of GOLD stages 1–4. Among
ex-smoking men the rates were increased in GOLD
stages 1–4. No increased hospital admission rates due to
obstructive lung disease was found among ex-smoking
ARTICLE IN PRESS
Table 3 Number of individuals (men), patients, and hospital admissions in relation to symptoms of chronic bronchitis, GOLD
stages 1–4 and smoking habits.
Smoking
status
Never-smoker Ex-smoker Smoker
GOLD
stage
N Patients HospAdm HospAdm/
1000PY
N Patients HospAdm HospAdm/
1000PY
N Patients HospAdm HospAdm/
1000PY
Ref.y 2792 1844 (66) 7533 148 (418) 2993 2099 (70) 9157 164 (314) 4430 3262 (74) 16 163 223 (631)
CB 49 31 (63) 148 129 (164) 54 44 (81) 229 275 (827) 215 178 (83) 986 317 (665)
1 246 170 (69) 604 134 (267) 405 303 (75) 1312 157 (226) 792 620 (78) 3481 250 (449)
2 127 85 (67) 444 223 (438) 173 128 (74) 790 280 (549) 710 585 (82) 3418 290 (431)
3 15 10 (67) 80 332 (673) 33 30 (91) 196 491 (839) 101 88 (87) 733 921 (4533)
4 7 5 (71) 36 267 (166) 8 7 (88) 58 890 (1707) 27 23 (85) 213 801 (882)
Notes numbers of individuals in the GOLD stages.
yRef.: reference group of individuals without symptoms of chronic bronchitis (CB) and with normal pulmonary function, patients
denotes number of ‘‘patients’’; individuals with at least one hospital admission during follow-up with percentage within brackets.
HospAdm denotes total number of hospital admissions , HospAdm/1000 PY denotes mean number of hospital admissions per 1000
person-year with standard deviation within brackets.
Table 4 Number of individuals (women), patients, and hospital admissions in relation to symptoms of chronic bronchitis,
GOLD stages 1–4 and smoking habits.
Smoking
status
Never-smoker Ex-smoker Smoker
GOLD N Patients HospAdm HospAdm/
1000PY
N Patients HospAdm HospAdm/
1000PY
N Patients HospAdm HospAdm/
1000PY
Ref.y 2593 1585 (61) 5418 133 (393) 993 650 (65) 2243 144 (370) 2174 1485 (68) 5809 181 (482)
CB 42 22 (52) 113 154 (274) 25 16 (64) 70 143 (236) 108 84 (78) 413 204 (242)
1 106 61 (58) 243 163 (531) 46 26 (57) 95 125 (208) 184 132 (72) 550 233 (477)
2 50 33 (66) 144 199 (447) 32 25 (78) 101 360 (857) 234 181 (77) 909 255 (364)
3 7 4 (57) 28 474 (822) 5 3 (60) 20 173 (255) 36 28 (78) 205 507 (672)
4 3 3 (100) 16 260 (268) 0 0 0 0 9 7 (78) 95 1023 (1126)
N denotes numbers of individuals in the GOLD stages.
yRef.: reference group of individuals without symptoms of chronic bronchitis (CB) and with normal pulmonary function, patients
denotes number of ‘‘patients’’; individual with at least one hospital admission during follow-up with percentage within brackets..
HospAdm denotes total number of hospital admissions, HospAdm/1000 PY denotes mean number of hospital admissions per 1000
person-year with standard deviation within brackets.
M. Ekberg-Aronsson et al.114women with symptoms of chronic bronchitis and among ex-
smoking women with GOLD stages 1–4. Among never-
smokers there were increased hospital admission rates due
to obstructive lung disease in stage 2 among women and
stages 3–4 among men.Hospital admissions due to cardiovascular disease
There were a total of 17 928 hospital admissions due to
cardiovascular disease either as a primary or as a secondary
diagnosis. The number of individuals hospitalised due to
cardiovascular disease was 5771. The number of hospital
admissions with cardiovascular diagnosis as the primary
diagnosis was 15 528 and the number with cardiovascular
disease as the secondary diagnosis was 6071. Thus 3671
hospital admissions had cardiovascular disease both as the
primary and the secondary diagnoses.Hospital admissions due to cardiovascular disease
in symptoms of chronic bronchitis and GOLD
stages 1–4
Among smoking men the hospital admission rates due to
cardiovascular disease were increased in GOLD stages 2 (P-
value 0.002) and stage 3 (P-value 0.02) but after adjustment
for age this difference disappeared (Figure 4, Table A3 in
Appendix A). Increased hospital admission rates due to
cardiovascular disease were found among never-smoking
men of stage 2 (P-value 0.004). The rates were not increased
among never-smoking and ex-smoking women.
Discussion
This population based study of middle-aged individuals
showed a substantial morbidity with increased hospital
ARTICLE IN PRESS
1000
900
800
700
600
500
400
300
200
100
0
Ref CB 1 2 3 4 Ref CB 1 2 3 4
MEN WOMEN
<0.0001
0.02
<0.0001
0.008
0.001 0.2
<0.0001 0.2
50:th percentile
75:th percentile
25:th percentile
p-value
0.01
0.009
Figure 2 Hospital admissions in symptoms of chronic bronchitis and GOLD stages 1–4 among smokers. For comparison between
symptoms of chronic bronchitis, GOLD stages 1–4 and the reference-group, the hospital admission rates per 1000 person-years is
presented with the 20th, 50th and 75th percentiles. The P-value represents results from ordinal regression analyses of hospital
admission rates between symptoms of chronic bronchitis (CB), GOLD stages 1–4 and the reference-group. Ref.: reference group of
individuals without symptoms of chronic bronchitis and with normal pulmonary function.
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Figure 3 Hospital admission rates due to obstructive lung diseases in symptoms of chronic bronchitis and GOLD stages 1–4 among
smokers. For comparison between symptoms of chronic bronchitis, GOLD stages 1–4 and the reference-group the hospital admission
rates due to obstructive lung disease per 1000 person-years is presented with the 50th, 75th and 95th percentiles. The P-value
represents results from comparison of hospital admission rates between symptoms of chronic bronchitis (CB), GOLD stages 1–4 and
the reference-group with ordinal regression with adjustment for age. Ref.: reference group of individuals without symptoms of
chronic bronchitis and with normal pulmonary function.
Hospital admission rates with symptoms of CB and airflow limitation corresponding to the GOLD stages of COPD 115admission rates due to all causes and obstructive lung
disease among those who smoked, with symptoms of chronic
bronchitis and preserved normal pulmonary function and
among those with airflow limitation corresponding to GOLD
stages 1–4 as compared to the reference group of those who
smoked without symptoms of chronic bronchitis and with
normal pulmonary function. Furthermore, GOLD stages 2and 4 showed an increased cardiovascular morbidity among
women who smoked as compared to the reference.
In a previous study we reported an increased all-cause
mortality risk associated with symptoms of chronic bron-
chitis. The magnitude of the risk was similar to that of GOLD
stage 2.18 Similar findings concerning mortality among
individuals with symptoms of chronic bronchitis has also
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Figure 4 Hospital admission rates per 1000 person-years due to cardiovascular disease in symptoms of chronic bronchitis and GOLD
stages 1–4 among smokers. For comparison between symptoms of chronic bronchitis, GOLD stages 1–4 and the reference-group the
hospital admission rates due to cardiovascular disease per 1000 person-years is presented with the 50th, 75th and 95th percentiles.
The P-value represents results from comparison of hospital admission rates between symptoms of chronic bronchitis (CB), GOLD
stages 1–4 and the reference-group with ordinal regression with adjustment for age. Ref.: reference group of individuals without
symptoms of chronic bronchitis and with normal pulmonary function.
M. Ekberg-Aronsson et al.116been reported previously from a study conducted in a
population of working men23 and from the Atherosclerosis in
Communities (ARIC) study.24 Symptoms of chronic bronchitis
have been associated with an increased risk of death from
pulmonary infection.25,26 and have also been associated
with an increased risk of death due to lung cancer.18,27 In the
present study we have also found increased hospital
admission rates due to all causes among individuals with
symptoms of chronic bronchitis (hospital admissions due to
obstructive lung disease excluded). Moreover, among female
smokers with symptoms of chronic bronchitis, the hospital
admission rates due to obstructive lung disease were
increased as compared to the reference-group. Notably
only a small subgroup (X the 95th percentile) in the
symptomatic group of women showed increased rates. The
ICD codes used in this study to define hospital admissions
due to obstructive lung disease do not refer specifically to
an exacerbation. However, it is reasonable to assume that
these hospital admissions would be caused by an exacerba-
tion of COPD.8 Our findings suggest that in contrast to some
other studies5,28 there might be a possibility that individuals
with symptoms of chronic bronchitis develop significant
COPD. We have no follow-up data on lung function to
address this issue but findings from another Swedish study
support this view.29
The hospital admission rates due to all causes (excluding
hospital admissions due to obstructive lung disease) were
increased in GOLD stages 1–4 among smokers of both
genders. Several previous studies on COPD-related morbidity
have been conducted on patients with a known diagnosis of
COPD, mostly based on hospital discharge diagnoses of
COPD. In a study conducted in the US on a nationally
representative sample, any mention of COPD in thedischarge diagnosis was associated with a higher prevalence
and in-hospital mortality for pneumonia, congestive heart
failure, ischaemic heart disease, thoracic malignancies, and
respiratory failure.12 In the Lung Health Study of individuals
with known mild-to-moderate COPD, a total of 12.8% of
participants were hospitalised with cancer, cardiovascular
disease, and non-malignant respiratory disease accounting
for 75% of hospital admissions.30 COPD is under-diagnosed
also among hospitalised medical patients31 and COPD
patients may not be identified in register-based studies.29,31
Our findings could thus provide some knowledge regarding
the long-term morbidity in terms of hospital admissions due
to other causes than COPD among individuals with airflow
limitation.
Obstructive lung disease is frequently not listed as the
underlying or contributing cause of hospitalisation.31 In this
study, the hospital admission rates due to obstructive lung
disease were increased among those who smoked with
GOLD stages 1–4. This was more pronounced among
subgroups of smoking women with severe COPD. In general
the differences in the admission rates between groups were
in the 75th–90th percentile indicating that there were
subgroups of individuals within the GOLD stages 1–4 who
had repeated hospital admissions due to obstructive lung
disease.8,32 However, a majority of the individuals with
airflow limitation showed no hospital admissions due to
obstructive lung disease at all. Due to the well-known
under-diagnosis of COPD4,29,31 our findings probably repre-
sent an underestimation of the true hospital admission rates
due to obstructive lung disease among individuals with
airflow limitation.4
Low FEV1 has been associated with an increased risk of
cardiovascular disease in previous studies.9 Register-based
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a known diagnosis of COPD from Canada and the US have
shown an increased risk of hospital admission due to
cardiovascular disease among individuals with COPD as
compared to those without COPD.10,11,33 The hospital
admission rates due to cardiovascular disease were
increased among smoking women with airflow limitation
(GOLD stages 2 and 4) and among never-smoking men of
GOLD stage 2, which is in line with these findings.
A possible explanation for an increased all-cause mortality
and morbidity among individuals with symptoms of chronic
bronchitis with or without signs of airflow limitation could be
an increased systemic inflammatory response.34 A systemic
inflammatory response has been demonstrated among
individuals with symptoms of chronic bronchitis with and
without airways obstruction.34 The systemic inflammation
might be the link between inflammatory lung disorders such
as symptoms of chronic bronchitis and COPD, cardiovascular,
other cardiorespiratory diseases and respiratory cancers.34,35
Some methodological aspects should be pointed out. This
population-based study comprised a large number of
smoking men and women with information about respiratory
symptoms, smoking habits and lung function measurements.
Smoking habits at baseline have been validated with
biochemical markers in a previous study.19 The follow-up
time was substantial with a large number of hospital
admissions.
A number of other possible limitations have been
discussed previously.18,19 The protocol of the lung function
tests did not fully meet the standards of the current
recommendations.20 The values of internal regression
equation based on length and age and the standard
deviation of the equation was similar to that of the Working
party of the European Community for Steel and Coal.36 We
therefore believe that the methodological error is similar to
that achieved after optimal spirometric technique.
There remains a possibility of misclassification depending
on reduced specificity in the spirometries, which would
result in an underestimation of the results rather than
the reverse. Another possible limitation is that the
GOLD classification of COPD requires post-broncho-dilator
values, which were not available in this study.1 In an
epidemiological setting the administration of broncho-
dilatation is often not feasible. The use of pre-broncho-
dilator values seems to be an acceptable alternative but the
results should be interpreted in this context.6 Thus, there is
a possibility that individuals with asthma were included
among some smokers with signs of airflow limitation.
Notably, hospital admissions due to asthma were also
included in the analyses due to an overlap in the hospital
discharge diagnoses.
Furthermore, smoking habits were assessed at one point
in time and not repeated thereafter and some smokers in
this study are likely to have stopped smoking during the
follow-up time37 causing a misclassification of ex-smokers as
continuing smokers.
In addition, we have no follow-up data on symptoms of
chronic bronchitis and thus we are not able to determine
whether the symptoms of chronic bronchitis were stable or
not. Symptoms of chronic bronchitis may disappear in some
individuals especially in ex-smokers.5 In these individuals,
symptoms of chronic bronchitis may have had a limitedinfluence on hospital admission rates and could cause an
underestimation of the effect of persistent symptoms of
chronic bronchitis in this study.
Further, the local patient register started in 1974 and was
amongst the first in this country to register hospital
admissions. However, the register was only considered
complete in 1979; thus, there is a possibility that some
hospital admissions might be missed from 1974 to 1979.
Individuals not selected to this study for any reason
(no spirometry, lack of data on smoking habits) showed
similar distribution of socio-economic groups as compared to
the selected groups in both genders. Men who were not
selected were somewhat younger, (mean age 38.7 years) and
perhaps healthier as compared to the selected group (46.4
years). Women who were not selected were slightly older
(54.3 years) as compared to selected women (47.5 years).
The prevalence of smoking was similar in both groups of
men, but lower among women who were not selected,
(15%), as compared to the selected women (47.5%). Finally,
a potential limitation is the fact that we have no information
regarding the distribution of the study interventions and thus
we are not able to adjust for effects of the intervention part
of the study. A previous study conducted on the MPP, birth
cohorts invited to screening examination were compared to
birth cohorts not invited.16 In that study, total mortality did
not differ significantly between the intervention group and
control group.16 Regarding the effect of non-participation, in
the same study,16 non-participants showed a two-fold
increased mortality risk as compared to participants.
In summary, among smokers, symptoms of chronic bron-
chitis and airflow limitation corresponding to GOLD stage 2–4
conveyed a substantial morbidity with increased hospital
admission rates due to all causes, and due to obstructive lung
disease. Airflow limitation corresponding to GOLD stages 2 and
4 increased cardiovascular morbidity among women. Hence,
the burden of disease associated with symptoms of chronic
bronchitis and COPD could be underestimated.
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Ethical approvalTable A2 Hospital admission rates per 1000 person-years due t
bronchitis and GOLD stages 1–4 among smokers.
Men
GOLD COPD Asthma OLD Median 75th
perc
95th
perc
P-value
Ref.y 97 15 225 0 0 0
CB 7 0 16 0 0 7 0.05
1 44 8 93 0 0 40 o0.0001
2 140 26 279 0 0 99 o0.0001
3 128 58 268 0 107 937 o0.0001
4 39 7 61 0 128 1887 o0.0001
COPD; numbers of hospital admissions due to COPD, asthma (primary
hospital admissions due to both COPD and asthma (primary and seco
For comparison between symptoms of chronic bronchitis, GOLD sta
to obstructive lung disease per 1000 person-years is presented with
results from comparison of hospital admission rates between symptom
group with ordinal regression with adjustment for age.
yRef.: reference group of individuals without symptoms of chronic
Table A1 Hospital admission rates per 100 person-years due to
GOLD stages 1–4 among smokers.
Men
GOLD 25th 50th 75th P-value
Ref.y 0 86 233
CB 48 149 336 o0.0001
1 38 127 297 0.02
2 43 136 334 o0.0001
3 51 166 386 0.008
4 88 234 884 0.01
For comparison between symptoms of chronic bronchitis, GOLD sta
1000 person-years is presented with the 20th, 50th, and 75th perc
analyses of hospital admission rates between symptoms of chronic b
yRef.: reference group of individuals without symptoms of chronic
Table A3 Hospital admission rates per 1000 person-years due
bronchitis and GOLD stages 1–4 among smokers.
Men
GOLD Total 50th Median 75th perc 95th perc P-value
Ref.y 4492 0 47 279
CB 232 0 52 267 0.88
1 1056 0 79 351 0.22This study has been approved by the Swedish Data register
authorities and the local Ethical committee of the Medical
Faculty, University of Lund.Appendix A
Hospital admission rates per 100 person-years in relation to symptoms of chronic bronchitis and GOLD stages 1–4 among
smokers, see Tables A1–A3.o obstructive lung disease in relation to symptoms of chronic
Women
GOLD COPD Asthma OLD 50th 75th
perc
95th
perc
P-value
Ref.y 23 3 61 0 0 0
CB 11 5 23 0 0 55 0.002
1 25 15 54 0 0 55 o0.0001
2 79 7 132 0 0 233 o0.0001
3 39 7 78 0 240 1068 o0.0001
4 21 3 54 219 1261 2876 o0.0001
diagnosis); numbers of hospital admissions due to asthma, OLD;
ndary diagnoses).
ges 1–4 and the reference group the hospital admission rates due
the 50th, 75th, and 95th percentiles. The P-value represents
s of chronic bronchitis (CB), GOLD stages 1–4 and the reference
bronchitis and with normal pulmonary function.
all causes in relation to symptoms of chronic bronchitis and
Women
GOLD 25th 50th 75th P-value
Ref.y 0 59 169
CB 44 123 230 0.001
1 0 81 218 0.2
2 0 118 284 o0.0001
3 0 105 274 0.21
4 156 216 608 0.009
ges 1–4 and the reference group the hospital admission rates per
entiles. The P-value represents results from ordinal regression
ronchitis (CB), GOLD stages 1–4 and the reference group.
bronchitis and with normal pulmonary function.
to cardiovascular disease in relation to symptoms of chronic
Women
GOLD Total 50th 75th perc 95th perc P-value
Ref.y 1076 0 0 171
CB 63 0 0 147 0.52
1 90 0 0 158 0.65
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Table A3 (continued )
Men Women
GOLD Total 50th Median 75th perc 95th perc P-value GOLD Total 50th 75th perc 95th perc P-value
2 973 0 76 433 0.20 2 178 0 52 284 0.007
3 212 0 116 770 0.35 3 31 0 79 404 0.21
4 53 0 226 842 0.38 4 12 0 227 260 0.04
For comparison between symptoms of chronic bronchitis, GOLD stages 1–4 and the reference group the hospital admission rates due
to cardiovascular disease per 1000 person-years is presented with the 50th, 75th, and 95th percentiles. The P-value represents results
from comparison of hospital admission rates between symptoms of chronic bronchitis (CB), GOLD stages 1–4 and the reference group
with ordinal regression with adjustment for age.
yRef.: reference group of individuals without symptoms of chronic bronchitis and with normal pulmonary function.
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